Need the life-sciences signal but short on time?
Get a free quarterly briefing: four pages on what life-sciences operators are actually saying about Biosecure, AI hype vs. substance, and the $50,000 cell-therapy question. Ten minutes, in your inbox.
Jim Kremidas spent 24 years at Eli Lilly, where he started the industry’s first Patient Recruitment Department. He’s been in clinical research for 35+ years. Then he got bladder cancer — the standard of care didn’t work — and he couldn’t find a clinical trial using the very tools he helped build. It took six people to connect him to a trial.
Elisa Cascade has 30+ years in clinical research technology. Former Chief Product Officer at Science 37 and Advarra. Past Chair of ACRP. She built a 2.7 million patient community for direct-to-patient recruitment back in 2010-2011 — bleeding edge for decentralized trials at the time.
In Today’s Episode We Discuss:
Resources:
Get a free quarterly briefing: four pages on what life-sciences operators are actually saying about Biosecure, AI hype vs. substance, and the $50,000 cell-therapy question. Ten minutes, in your inbox.
Free briefing
Four pages, ten minutes: the Biosecure Act, AI hype vs. substance, and the $50,000 cell-therapy question. Drop your email and it is in your inbox.
No spam. Unsubscribe anytime.
Check your inbox.
Your briefing is on its way.
